Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | FDPS | P14324 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427602 | 1.00 | TTR (0.69) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL1578505 | 0.94 | KDM4E (0.64) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL27792939 | 0.94 | KDM4E (0.64) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL1579811 | 0.94 | TTR (0.61) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL1578506 | 0.94 | KDM4E (0.64) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL27934208 | 0.94 | TTR (0.61) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL14299070 | 0.92 | TTR (0.60) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL3752885 | 0.92 | CA12 (0.69) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL1269502 | 0.92 | TTR (0.63) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL1269501 | 0.92 | TTR (0.63) | TTRDPP4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557126-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070254943-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-11-01 | — | — | US | disclosed |
| US-7250414-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050203167-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-4335054-A | Process for the preparation of alkenylbenzenecarboxylic acid derivatives and alkenylnaphthalenecarboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1982-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203167-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM1, CHRM2, CHRM3 | TTR 3671/4885DPP4 2062/4885CA12 3965/4885 |
| US-20070254943-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM1, CHRM2, CHRM3 | TTR 3671/4885DPP4 2062/4885CA12 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.